Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$194.29 USD

194.29
3,606,158

-1.16 (-0.59%)

Updated Oct 4, 2024 03:59 PM ET

After-Market: $193.91 -0.38 (-0.20%) 5:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

AbbVie (ABBV) Beats on Q3 Earnings, Lags Sales, Narrows '22 View

AbbVie's earnings (ABBV) beat estimates for third-quarter 2022, while sales miss the same. Shares drop in pre-market trading after it narrows down its full-year earnings guidance.

AbbVie (ABBV) Q3 Earnings Beat Estimates

AbbVie (ABBV) delivered earnings and revenue surprises of 2.81% and 0.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Shaun Pruitt headshot

Pfizer Earnings Preview: Growth & Diversification is Key

Pfizer's (PFE) Q3 earnings report on Tuesday, November 1 will give insight into its ability to sustain growth from its Covid-19 vaccines. The company's ability to beat earnings expectations may rely on the growth of other business units during the quarter.

Derek Lewis headshot

AbbVie Q3 Preview: Can Shares Continue Their Run?

AbbVie shares have been a bright spot in a dim market year-to-date, up a double-digit 17% and easily crushing the S&P 500's performance.

Will AbbVie's Immunology Drugs Continue to Drive Q3 Earnings?

AbbVie's (ABBV) third-quarter performance is expected to reflect the impact of strong demand for immunology and aesthetics products.

Pfizer (PFE) Reports Next Week: Wall Street Expects Earnings Growth

Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Zacks Analyst Blog Highlights J&J, Roche, Eli Lilly and AbbVie

J&J, Roche, Eli Lilly and AbbVie are part of The Zacks top Analyst Blog.

AbbVie (ABBV) to Report Q3 Earnings: What's in the Cards?

AbbVie (ABBV) third-quarter performance will likely reflect the impact of strong demand for immunology and aesthetics franchises. Investors will also enquire about ABBV's plans to counter Humira LOE.

AbbVie (ABBV) to Boost Immunology Pipeline With New Acquisition

AbbVie (ABBV) acquires UK-based DJS Antibodies Ltd to enhance its antibody research activities and strengthen the immunology portfolio.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ Q3 Earnings Beat, RHHBY Sales Weak, LLY, ABBV Ink M&A Deals

J&J (JNJ) beats earnings and sales estimates for the third quarter. Eli Lilly (LLY) and AbbVie (ABBV) announce small acquisitions.

AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AbbVie (ABBV) Stock Moves -0.14%: What You Should Know

In the latest trading session, AbbVie (ABBV) closed at $142.93, marking a -0.14% move from the previous day.

Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Do Options Traders Know Something About AbbVie (ABBV) Stock We Don't?

Investors need to pay close attention to AbbVie (ABBV) stock based on the movements in the options market lately.

AbbVie (ABBV) Gains As Market Dips: What You Should Know

AbbVie (ABBV) closed at $142.94 in the latest trading session, marking a +0.01% move from the prior day.

How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

AbbVie (ABBV) Stock Moves -1.09%: What You Should Know

AbbVie (ABBV) closed at $138.76 in the latest trading session, marking a -1.09% move from the prior day.

Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

Reata Pharma (RETA) is Striving Hard Despite Pipeline Setbacks

Reata Pharmaceuticals (RETA) is yet to generate product revenues due to the lack of marketed drugs in its portfolio. However, two of its pipeline candidates are close to potential FDA approval.

Can AbbVie's (ABBV) New Drugs Make up for Lost Humira Sales?

AbbVie's (ABBV) new drugs, Skyrizi and Rinvoq, are faring well, bolstered by approval in new indications. They are expected to drive revenues once Humira loses U.S. exclusivity in 2023.

Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now?

Smart Beta ETF report for HDV

AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know

AbbVie (ABBV) closed at $141.21 in the latest trading session, marking a -1.29% move from the prior day.

Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

AbbVie (ABBV) Gets CHMP Nod for Skyrizi in a Third Indication

The CHMP recommends authorizing AbbVie's (SNY) Skyrizi as a treatment for Crohn's disease. The drug is approved for treating plaque psoriasis and psoriatic arthritis indications.